Add to ORKGSeveral genotypic interpretation scores have been proposed for the evaluation of susceptibility to lopinavir/ritonavir (LPV/r) but have not been compared using an independent data set. This study was a retrospective multicenter cohort of patients initiating LPV/r-based therapy. The virologic response (VR) was defined as a viral load of <500 copies/ml at week 24. The genotypic interpretation scores surveyed were the LPV mutation score, the ViroLogic score, the ATU score, the Stanford database score, and the International AIDS Society-USA mutation list. Of the 103 patients included in the analysis, 76% achieved VR at 24 weeks. For scores with clinical breakpoints defined (LPV mutation, ATU, ViroLogic, and Stanford), over 80% of the patients b...
We evaluated the virological outcome of lopinavir/ritonavir (LPV/RTV) in 224 HIV-1-infected and prot...
BACKGROUND: Several decision support systems have been developed to interpret HIV-1 drug resistance ...
For 95 protease inhibitor-experienced HIV-1-infected patients, the genotypic inhibitory quotient (GI...
Several genotypic interpretation scores have been proposed for the evaluation of susceptibility to l...
Tipranavir, a non-peptidic protease inhibitor which shows in vitro efficacy against some HIV-1-resis...
Objective: To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in pat...
The question of whether a score for a specific antiretroviral (e.g. lopinavir/r in this analysis) th...
Background: The question of whether a score for a specific antiretroviral (e.g. lopinavir/r in this ...
International audienceBACKGROUND: Different approaches using genotypic, pharmacokinetic parameters o...
BACKGROUND: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir ...
Background: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir ...
The aim of this study was to establish the prevalence and predictors of genotypic resistance of HIV-...
Interpretation of genotypic resistance to ritonavir-boosted saquinavir (SQV/r) is still incomplete d...
We evaluated the virological outcome of lopinavir/ritonavir (LPV/RTV) in 224 HIV-1-infected and prot...
BACKGROUND: Several decision support systems have been developed to interpret HIV-1 drug resistance ...
For 95 protease inhibitor-experienced HIV-1-infected patients, the genotypic inhibitory quotient (GI...
Several genotypic interpretation scores have been proposed for the evaluation of susceptibility to l...
Tipranavir, a non-peptidic protease inhibitor which shows in vitro efficacy against some HIV-1-resis...
Objective: To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in pat...
The question of whether a score for a specific antiretroviral (e.g. lopinavir/r in this analysis) th...
Background: The question of whether a score for a specific antiretroviral (e.g. lopinavir/r in this ...
International audienceBACKGROUND: Different approaches using genotypic, pharmacokinetic parameters o...
BACKGROUND: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir ...
Background: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir ...
The aim of this study was to establish the prevalence and predictors of genotypic resistance of HIV-...
Interpretation of genotypic resistance to ritonavir-boosted saquinavir (SQV/r) is still incomplete d...
We evaluated the virological outcome of lopinavir/ritonavir (LPV/RTV) in 224 HIV-1-infected and prot...
BACKGROUND: Several decision support systems have been developed to interpret HIV-1 drug resistance ...
For 95 protease inhibitor-experienced HIV-1-infected patients, the genotypic inhibitory quotient (GI...